Stephen Archer, MD: Treatment of pulmonary artery hypertension

Produced, interviewed by Steven Greer, MD

The pharmaceutical market for drugs treating pulmonary artery hypertension (PAH) has exploded over the last 5 years. Once a disease treated by orphan-status drugs, Big Pharma entered the market with Viagra and Cialis renamed (Revatio and Adcirca respectively).

Dr. Stephen Archer, Chief of Cardiology at the University of Chicago Medical Center, and pioneer in the field of PAH, discusses the treatment algorithm for PAH. In addition to Dr. Archer’s research making him qualified, he is very unique in not having industry conflicts with the drugs he discusses.